PDF(Pubmed)
Abstract：
Urinary tract infections (UTIs) rank among the most prevalent bacterial infections in children. Probiotics appear to reduce the risk of recurrence of UTIs. This study aimed to evaluate whether probiotics containing Lactobacillus rhamnosus PL1 and Lactobacillus plantarum PM1 therapy prevent UTIs in the pediatric population compared to a placebo. A superiority, double-blind, randomized, controlled trial was conducted. In total, 54 children aged 3-18 years with recurrent UTIs or ≥one acute pyelonephritis and ≥one risk factor of recurrence of UTIs were randomly assigned (27 patients in each arm) to a 90-day probiotic or placebo arm. The age, sex, diagnosis, renal function, risk factors, and etiology of UTIs did not vary between the groups. During the intervention, 26% of children taking the probiotic had episodes of UTI, and it was not significantly less than in the placebo group. The number of UTI episodes during the intervention and the follow-up period decreased significantly in both groups, but the difference between them was insignificant. We observed a decrease in UTIs during the study of almost 50% in the probiotic group compared to the placebo group. Probiotics can be used as natural, safe prophylaxis for children with risk factors for UTIs in whom antibiotic prevention is not indicated.
摘要：
尿路感染（UTI）是儿童中最常见的细菌感染之一。益生菌似乎可以降低UTI复发的风险。这项研究旨在评估与安慰剂相比，含有鼠李糖乳杆菌PL1和植物乳杆菌PM1治疗的益生菌是否可以预防儿科人群的UTI。一种优势，双盲,随机化，进行了对照试验。总的来说,将54名年龄在3-18岁的复发性尿路感染或≥1例急性肾盂肾炎和≥1例尿路感染复发危险因素的儿童(每组27名患者)随机分配到90天益生菌或安慰剂组。年龄,性别,诊断,肾功能,危险因素，两组间尿路感染的病因没有差异。在干预期间,服用益生菌的儿童中有26％患有UTI，并没有显著低于安慰剂组。干预期间和随访期间的UTI发作次数两组均显著减少,但他们之间的差别是微不足道的。与安慰剂组相比，我们观察到益生菌组研究期间UTI减少了近50％。益生菌可以作为天然的，对于有UTI危险因素且未进行抗生素预防的儿童进行安全预防.
